Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Mindless use of weight loss drugs can cause the weight to return later. (Photo credit: iStock)
Weight loss drugs appeal to many for their convenience, but according to some experts, there are a number of noteworthy side effects. From rapid weight gain to sagging skin, several side effects of weight loss drugs have been identified through studies. Now, new research has found that weight loss drugs can cause more muscle loss than clinical expectations. The results, presented at the American College of Physicians Internal Medicine (ACP-IM) meeting in San Francisco, add to existing evidence on the possible adverse effects of GLP-1.
When a person loses a considerable amount of weight, they also lose bone mass, muscle mass, and some connective tissue. Experts at the University of North Carolina at Chapel Hill found that no studies directly associate muscle loss with a decline in physical function or strength. However, this clinical gap underscores the need to assess strength and mobility alongside weight loss in patients receiving this therapy. The systematic review identified 36 randomised clinical trials that measured changes in muscle mass and fat among adults using incretin-based obesity medications such as tirzepatide, dulaglutide, or semaglutide.
Each study measured body composition using MRI, CT scans, and bioelectrical impedance analysis. Most of them used DEXA along with other methods to obtain information about lean muscle mass, bone mineral density, and the distribution of body fat. The average age of participants ranged from 20 to 63.7 years. Only four studies included participants aged 60 years and above. None of the studies focused on adults aged 65 years or older.
Researchers noted a concerning trend: patients’ estimated muscle loss exceeded the 25 per cent threshold. Clinicians had expected a 25 per cent reduction, but not more than that. Experts also found that 68 per cent of people who used the drugs exceeded the 25 per cent benchmark, compared to 50 per cent of those who relied on placebos and lifestyle interventions. None of the studies measured whether the loss of muscle mass was correlated with function or strength loss.
Despite being a concerning side effect of weight loss drugs, muscle mass is likely to diminish anyway with age. Additionally, the loss is more significant in older adults. Therefore, doctors advise caution when prescribing these drugs to individuals who are more prone to losing muscle function at an advanced age. Ideally, doctors should recommend exercise or physical therapy to patients taking weight loss medications.
The final word
According to experts, weight loss drugs do have a positive side — and that extends beyond obesity treatment. These drugs are also beneficial for diabetes and help reduce the risk of cardiovascular disease. However, it is important to support treatment with the right kind of diet and a proper exercise regimen. Solely depending on the medication can lead to weight gain once it is discontinued. Therefore, for healthy weight loss, it is best to rely on sustainable methods for long-lasting results.
Sadhguru recommended some tips for sustainable weight loss. (Photo credit: AI generated)
Indian guru and founder of the Isha Foundation, Sadhguru, offers a different perspective on life and mental health. In a 2025 talk, he spoke about weight loss. At a time when obesity, metabolic, and lifestyle disorders are at an all-time high, there is an urgent need to revisit and fix the way one eats. While many turn to diet fads and practise calorie or food group restrictions, Sadhguru recommends the contrary. The 68-year-old emphasises the importance of sustainable weight management through balanced choices, mindful eating and meals aligned with the body’s natural rhythm.
Many people aim to lose weight to deal with body image issues or to prepare for a special upcoming occasion. However, according to Sadhguru, one must not try to force discipline through restriction, but instead allow the body to regulate itself efficiently while maintaining energy levels. If you are looking for foods to include in your diet for sustainable weight loss, here are some recommendations:
Constipation is a consequence of poor gut health. (Photo credit: iStock)
Eat healthy meals and follow a proper diet plan; your diet must be balanced—many have grown up listening to these healthy recommendations. However, little do we realise just how much difference healthy habits make to our lives. Even when it comes to constipation, one barely understands the long-term repercussions of irregular trips to the loo and how this may impact overall health. According to a 2023 review, prominent differences can be noticed in the gut microbiomes of 'slowpokes' and 'speeders.' Because the gut is strongly linked to overall health, there are several health implications that often go unnoticed.
Constipation refers to a state wherein one fails to pass stools at least three times a week. Slow transit, too, is associated with inflammatory and metabolic disorders—and even Parkinson’s disease. Experts say that identifying microbiome profiles linked to gut transit time could help develop a fresh approach to treating and managing these conditions. Experts involved in the study explained how bidirectional interactions between transit time and gut microbiota provide a useful way to understand gut microbiome variations in both disease and health.
Experts say that the gut microbiome, in both activity and composition, plays a crucial role in health. From diet to exercise, it can be shaped by various factors. For this, experts evaluated the impact of holding in stool and its consequent effects on health. They analysed previously published research on gut transit time, diet, gut microbiome composition, stool consistency, and metabolites released. Experts found that the studies involved thousands of participants—both healthy individuals and those dealing with comorbidities such as liver cirrhosis, irritable bowel syndrome and constipation. However, this required swallowable capsules with sensors to track their journey through the digestive tract.
Another method used was the Bristol Stool Scale—a diagnostic tool that classifies stool based on whether it resembles hard pellets or watery mush. Some studies also tracked how long participants took to pass sweetcorn or blue dye. The goal was the same — estimating how long food remains in the colon. The longer it stays, the more time bacteria have to regulate gut acidity, ferment components, and produce metabolites that influence overall health.
The research team yielded interesting results — people with faster gut transit had different microbiomes compared to those with slower transit times. This helped provide better predictions for gut microbiota than a simple test alone. It was also found that faster gut transit times were associated with microbiomes dominated by faster-growing species that thrived on a low-fat, high-carbohydrate diet. Slower transit times, however, were linked to microbiomes influenced by diets high in protein. These extremes can reduce gut microbiome diversity compared to average transit times. Therefore, both fast and slow movement create environments where specific species dominate.
Collectively, the research showed that gut transit time is an overlooked tool for understanding how the gut functions, its role in overall health, and how people respond to treatments such as probiotics. This could also explain why the same gut health advice does not work for everyone. Two people can consume the same meal and still show different results, suggesting that an individual's gut rhythm can help tailor dietary advice and treatment to suit their body.
The research is published in the journal Gut.
© 2024 Bennett, Coleman & Company Limited